Artrya Limited · ASX:AYA
Artrya — Q3 FY2025 Earnings Presentation
6 slides from Artrya's earnings presentation, May 1, 2025
Slide 1: April 2025 Quarterly Call
For personal use only April 2025 Quarterly Call 1 May 2025 1
Slide 2: 3Q FY2025 Quarterly Report
3Q FY2025 Quarterly Report • Receives milestone Food and Drug Administration (FDA) 510(k) clearance for Salix® Coronary Anatomy for commercial sale in the US. Salix® Coronary Anatomy to be formally launched across hospital systems in the US • Secures three-year commercial contracts with Sonic Health
Slide 3: Pathway to revenue
Pathway to revenue FDA Roadmap Shortening the pathway to revenue 1. Salix Coronary Anatomy (FDA Cleared) • First revenues from three US partners expected For personal use only in CY25 Cleared on 28 March 2025 • Scale the channel 2. Salix Coronary Plaque (SCP) o Without need of large sales team Estim
Slide 4: SAPPHIRE Study
SAPPHIRE Study Salix-based Analysis of Plaque to identify Patients at HIgher Risk of Events SAPPHIRE aims to: 1. novel plaque dispersion score (PDS) better risk assessment compared to current For personal use only methods 2. demonstrate that the PDS can be used to appropriately guide medical therapy
Slide 5: Salix is built to target all pillars across the care continuum
Salix® is built to target all pillars across the care continuum Artrya’s product pipeline goes further & moves us towards predicting the patient at risk. For personal use only Whole Heart Disease Structural Optimised Characterisation Severity Assessment Procedure Detailed Plaque and Dispersion Non-i
Slide 6: Thank You
For personal use only 6 Thank You